Reneo Pharmaceuticals Inc
NASDAQ:RPHM
Intrinsic Value
Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. [ Read More ]
The intrinsic value of one RPHM stock under the Base Case scenario is 9.77 USD. Compared to the current market price of 1.65 USD, Reneo Pharmaceuticals Inc is Undervalued by 83%.
Valuation Backtest
Reneo Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling RPHM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Reneo Pharmaceuticals Inc
Current Assets | 106.6m |
Cash & Short-Term Investments | 103m |
Other Current Assets | 3.7m |
Non-Current Assets | 814k |
PP&E | 733k |
Other Non-Current Assets | 81k |
Current Liabilities | 18.2m |
Accounts Payable | 8.7m |
Accrued Liabilities | 9.5m |
Non-Current Liabilities | 649k |
Other Non-Current Liabilities | 649k |
Earnings Waterfall
Reneo Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-83.1m
USD
|
Operating Income
|
-83.1m
USD
|
Other Expenses
|
5.7m
USD
|
Net Income
|
-77.4m
USD
|
Free Cash Flow Analysis
Reneo Pharmaceuticals Inc
RPHM Profitability Score
Profitability Due Diligence
Reneo Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Reneo Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
RPHM Solvency Score
Solvency Due Diligence
Reneo Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Reneo Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RPHM Price Targets Summary
Reneo Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RPHM is 1.71 USD with a low forecast of 1.01 USD and a high forecast of 3.15 USD.
Ownership
RPHM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RPHM Price
Reneo Pharmaceuticals Inc
Average Annual Return | -54.28% |
Standard Deviation of Annual Returns | 25.55% |
Max Drawdown | -91% |
Market Capitalization | 55.1m USD |
Shares Outstanding | 33 420 808 |
Percentage of Shares Shorted | 14.55% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company is headquartered in Irvine, California and currently employs 20 full-time employees. The company went IPO on 2021-04-09. The firm is focused on the developing therapies for patients with rare genetic mitochondrial diseases. The firm is engaged in developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to transcription of genes involved in mitochondrial function and fatty acid oxidation (FAO). The firm is developing REN001 in the three rare genetic diseases that present with myopathy and have unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). The firm has completed Phase I b clinical trial in patients with PMM to REN001. The company is conducting open-label Phase I b clinical trials of REN001 with LC-FAOD and with McArdle disease.
Contact
IPO
Employees
Officers
The intrinsic value of one RPHM stock under the Base Case scenario is 9.77 USD.
Compared to the current market price of 1.65 USD, Reneo Pharmaceuticals Inc is Undervalued by 83%.